WO2004019837A1 - Medicinal product packaging - Google Patents
Medicinal product packaging Download PDFInfo
- Publication number
- WO2004019837A1 WO2004019837A1 PCT/US2003/025841 US0325841W WO2004019837A1 WO 2004019837 A1 WO2004019837 A1 WO 2004019837A1 US 0325841 W US0325841 W US 0325841W WO 2004019837 A1 WO2004019837 A1 WO 2004019837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- container
- medicinal preparation
- medicinal
- barrier layer
- body wall
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the invention relates to use of fluorinated plastic containers for medicinal products, particularly for highly potent medicinal preparations.
- Medicinal products must possess certain levels of stability and purity in order to be suitable for safe and efficacious administration to patients. Medicinal products are considered stable if the active ingredient can maintain its strength at the level specified on the label for the maximum anticipated shelf-life under given environmental conditions.
- a medicinal product is considered unstable when the active ingredient or excipients such as preservatives, flavoring agents, loses sufficient potency to adversely affect the safety or efficacy of the drug or falls outside labeled specifications.
- a typical example of relatively unstable medicinal agents is prostaglandin.
- the potency of a drug product may decline over time during storage due to various reasons, such as degradation of the active ingredient, reaction of the active ingredient with excepients or container materials, or leaching of the active ingredient through the container wall or absorption of the active ingredient into the container wall.
- many medicinal preparations contain preservatives, such as chlorobutanol, phenoxyethanol, methyl, and propyl parabens and benzalkonium chloride, as certain concentrations, which enable storage of the medicinal preparations for periods of time up to 24 months or more.
- the preservatives may permeate the container wall upon storage, reducing the concentration in the preparation, and as a result their preservative value is diminished.
- containers used for packaging medicinal preparations can significantly affect the stability and purity of the preparations.
- Containers commonly used for medicinal products include glass containers, polypropylene containers, and polyethylene containers. Glass containers and polypropylene containers are said to be superior in maintaining stability of prostaglandin preparations (See U.S. Patent No. 6,235,781) and to have good permeability resistance to chlorobutanol (See U.S. Patent No. 5,799,837).
- Typical user-friendly containers, or dispensers, or bottles, for medicinal preparations are formed from, for example, polyethylene, polypropylene (PP), polyethylene terpthalates (PET), which in most instances provide a suitable combination with a pharmaceutical preparation which results in a packaged medicinal product that is user-friendly for dispensing of the pharmaceutical preparation on a drop-by-drop basis.
- PP polypropylene
- PET polyethylene terpthalates
- Plastic containers particularly containers made up of low density polyethylene however, have significant drawbacks.
- polyethylene is permeable to many active agents or excipients.
- chlorobutanol as a preservative
- upon storage chlorobutanol permeates the container wall and evaporates, reducing the concentration in the preparation. Accordingly, its preservative value to the pharmaceutical preparation is diminished. This phenomenon occurs over a matter of days, depending on the storage temperature. If the chlorobutanol content in a medicinal preparation is reduced by about 40% due to loss through a container wall, the medicinal preparation may no longer meet preservative specifications. As hereinabove mentioned, this can occur in a matter of days if the container is formed from 100% polyethylene.
- containers made up of LDPE may be permeable to label-related extractables such as adhesives, inks, varnishes, and curing agents. That is, when labels are placed on the outside of a LDPE container, extractable components from the label system may migrate from the label through the bottle wall and into the product matrix. The appearance of extractable components in the product matrix raises concern from several perspectives, including toxicity and patient exposure, and possible reduction of product stability due to interaction with formulation ingredients. This is particular true when benzalkonium chloride is utilized as a preservative.
- U.S. Patent No. 6,235,781 discloses that prostaglandin preparations stored in PE container were not as stable as those stored in glass containers or polypropylene containers.
- the invention provides for packaged medicinal product having extended shelf-life comprising:
- extended shelf-life means the shelf-life of the medicinal preparation packaged in a container having a fluorinated barrier layer on a surface of the body wall is longer than that of the same medicinal preparation packaged in an identical plastic container except that the container does not have a fluorinated barrier layer.
- the invention provides for a packaged medicinal product having extended shelf-life comprising:
- the invention provides for a packaged medicinal product having extended shelf-life comprising:
- a medicinal preparation (a) a medicinal preparation; and (b) a plastic container having a fluorinated barrier layer on a surface of the body wall, wherein the body of the container is filled with the medicinal preparation, wherein the container is a small volume bottle.
- the invention provides for a packaged medicinal product having extended shelf-life comprising: (a) a medicinal preparation; and
- the invention provides a method of packaging a medicinal preparation, said method comprising the steps of: (a) providing a plastic container having a fluorinated barrier layer on a surface of its body wall; and (b) filling the container body with the medicinal preparation.
- the invention provides for a method of packaging a medicinal preparation, said method comprising the steps of: (a) providing a plastic container having a fluorinated barrier layer on a surface of its body wall; and
- the invention provides for a method of packaging a medicinal preparation, said method comprising the steps of:
- the invention provides for a method of packaging a medicinal preparation, said method comprising the steps of:
- the invention provides for a method of increasing the stability of a liquid medicinal preparation, said method comprising packaging the liquid medicinal preparation in a plastic container having a fluorinated barrier layer on a surface of the container body wall.
- the term “increasing the stability” refers to maintaining the strength or potency of the preparation within given levels for a longer period of time, or maintaining the strength or potency of the preparation at higher levels within a given period of time, as compared with the preparation stored in an identical container except the container does not have a fluorinated barrier layer. Methods of determining the stability of a medicinal preparation is known in the art.
- the invention provides for a method of increasing the stability of a liquid medicinal preparation, said method comprising packaging the liquid medicinal preparation in a plastic container having a fluorinated barrier layer on a surface of the container body wall, wherein the liquid medicinal preparation comprises a prostaglandin.
- the invention provides for a method of increasing the stability of a liquid medicinal preparation, said method comprising packaging the liquid medicinal preparation in a plastic container having a fluorinated barrier layer on a surface of the container body wall, wherein the liquid medicinal preparation is for ophthalmic use.
- the invention provides for a method of increasing the stability of a liquid medicinal preparation for ophthalmic use, said method comprising packaging the liquid medicinal preparation in a plastic container having a fluorinated barrier layer on a surface of the container body wall, wherein the liquid medicinal preparation comprises a prostaglandin.
- the invention provides for a method of preventing loss of an ingredient in a liquid medicinal preparation through the wall of a plastic container which contains the medicinal preparations, said method comprising packaging the medicinal preparation in a plastic container having a fluorinated barrier layer on a surface of its body wall.
- preventing loss refers to reducing the loss of the ingredient to any extent. Depending on the specific ingredient of interest, the loss may be slightly reduced or may be completely prevented.
- the ingredient whose loss is desired to be prevented with the method of the invention can be an active ingredient or an excipient in the preparation.
- the invention provides for a method of preventing loss of an ingredient in a liquid medicinal preparation through the wall of a plastic container which contains the medicinal preparations, said method comprising packaging the medicinal preparation in a plastic container having a fluorinated barrier layer on a surface of its body wall, wherein the active ingredient is a prostaglandin.
- the invention provides a method of reducing transfer of an impurity into a liquid medicinal preparation upon storage, comprising packaging the liquid medicinal preparation in a plastic container said container having a fluorinated barrier layer on a surface of the container body wall.
- impurity refers to a component in a medicinal preparation packaged in a container which component is not a desired ingredient in the preparation and is introduced into the preparation from or through the wall of the container.
- An impurity may have its origin in the container wall materials, or, if a label is attached to the outside of the container, in label-related materials such as adhesives, inks, varnishes, and curing agents, or in the environment wherein the packaged preparation is stored, such as secondary packing materials.
- the term "medicinal preparation” refers to matter of compositions whose biological, physiological, pharmacological, or chemical activities are beneficial for animals or humans in normal or pathological conditions, such as diagnosis, prognosis, treatment, prophylaxis, therapy, or for animal production.
- Any suitable medicinal preparation may be incorporated into the present invention.
- the medicinal preparations are not limited by their specific applications, physical forms, formulations, or specific dosage forms.
- the preparations can be in the form of power, capsule, tablet, or liquid and any other forms.
- Liquid preparations are more advantageously suitable for incorporation into the present invention, and can be a suspension, solution, emulsion, or in other liquid form, or can be aqueous or non-aqueous.
- the medicinal preparations suitable for incorporation into the present invention are not limited by their usage or indication, or the potency, physical, chemical, pharmacological, or biological nature of their ingredients. It is more advantageous, however, that preparation comprises a highly potent active ingredient.
- highly potent active ingredient include, but not limited to, anticancer agents; anti-HIV agents; anti-toxins; hormones; steroids; potent pain killers etc.
- a specific example of highly potent active ingredient is prostaglandin.
- the terms "prostaglandin” and "PG” are generally used to describe a class of compounds which are analogues and derivatives of prostanoic acid.
- PG's may be further classified, for example, according to their 5-membered ring structure, using a letter designation; PG's of A-J series are known. PG's may be further classified based on the number of unsaturated bonds on the side chain, e.g., PG1 's (13,14-unsaturated), PG2 's (13,14- and 5,6-unsaturated), and PG3 's (13,14-,5,6- and 17,18-unsaturated). See U.S. Pat. No. 5,631,287.
- Various prostaglandins and prostaglandin preparations are also disclosed in US patent No. 6,235,781.
- prostaglandins which may be utilized in the present invention include all pharmaceutically acceptable prostaglandins, their derivatives and analogues, and their pharmaceutically acceptable esters and salts.
- Such prostaglandins include the natural compounds: PGE1, PGE2, PGE3, PGFl ⁇ ., PGF2 ⁇ ., PGF3 ⁇ , PGD2 and PGI2 (prostacyclin), as well as analogues and derivatives of these compounds which have similar biological activities of either greater or lesser potencies.
- Analogues of the natural prostaglandins include but are not limited to: alkyl substitutions (e.g., 15-methyl or 16,16-dimethyl), which confer enhanced or sustained potency by reducing biological metabolism or alter selectivity of action; saturation (e.g., 13,14-dihydro) or unsaturation (e.g., 2,3-didehydro, 13,14-didehydro), which confer sustained potency by reducing biological metabolism or alter selectivity of action; deletions or replacements (e.g., 11-deoxy, 9-deoxo-9-methylene), chloro (or halogen) for oxygen (e.g., 9beta.-chloro), oxygen for carbon (e.g., 3-oxa), lower alkyl for oxygen (e.g., 9-methyl), hydrogen for oxygen (e.g., 1-CH2 OH,l-CH2 OAcyl) which enhance chemical stability and/or selectivity of action; and .omega.-chain modifications (e.g., 18,
- Derivatives of these prostaglandins include all pharmaceutically acceptable salts and esters, which may be attached to the 1-carboxyl group or any of the hydroxyl groups of the prostaglandin by use of the corresponding alcohol or organic acid reagent, as appropriate. It should be understood that the terms “analogues” and “derivatives” include compounds that exhibit functional and physical responses similar to those of prostaglandins per se.
- Xalatan ® is an aqueous ophthalmic solution of latanoprost, which contains 50 micrograms/mL of latanoprost, 0.02% benzalkonium chloride as a preservative, and inactive ingredients such as sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous and water for injection.
- Rescula® is an aqueous ophthalmic solution of unoprostone isopropyl, which contains 1.5 mg/mL of unoprostone isopropyl, 0.015% benzalkonium chloride as a preservative and inactive ingredients such as mannitol, polysorbate 80, edetate disodium, sodium hydroxide or hydrochloric acid (to adjust pH), and water for injection.
- benzalkonium chloride as a preservative and inactive ingredients
- mannitol polysorbate 80
- water for injection water for injection.
- ophthalmic preparations which are packaged in a wide variety of plastic bottles (small and large volume; polypropylene or PP, low density polyethylene or LDPE and high density polyethylene or HDPE etc.).
- Some ophthalmic formulations contain potent therapeutic agents (e.g.
- prostaglandins like latanoprost in Xalatan ® or travoprost in Travatan ®
- preservatives e.g. chlorobutanol, methyl- and propyl-parabens, benzalkonium chloride or BAC etc.
- stabilizers surfactants such as polysorbate 80, antioxidants etc.
- prostaglanidns, chlorobutanol and the parabens are known to be prone to sorptive losses by the container.
- the container for use with the invention can be made of any suitable thermoplastic materials.
- suitable thermoplastic materials include, but not limited to, polymers and copolymers of polystyrene, polyacrylonitrile, polyvinyl chloride, polyethylene terepthalates (PET) and PET copolyetster (PETG), polycarbonate, polymethacrylates, and particularly polyolefins.
- Polyolefins include, for example, polyethylene, polypropylene, polybutenes, polyisoprenes and polypentenes and copolymers and mixtures thereof.
- polyethylene or a blend of polyethylene and one or more other materials.
- Polyethylene is commonly divided into classes based on its density. Classes commonly used include low-density polyethylene (LDPE), medium-density polyethylene (MDPE) and high-density polyethylene (HDPE).
- LDPE low-density polyethylene
- MDPE medium-density polyethylene
- HDPE high-density polyethylene
- Table 2 lists typical values for some physical, mechanical and thermal properties of MDPE as used herein.
- HDPE may further include higher density polyethylenes beyond the density range of 0.941-0.97 g/cc listed here as typical.
- the container suitable for the invention can be made of polyethylene of any density, made of a blend of polyethylene of various densities, or made of a blend of polyethylene with other materials.
- the container of the invention is made of material comprising LDPE.
- the relative content of LDPE in the container materials can be adjusted accordingly.
- containers made of LDPE is more readily squeezable than container made of MDPE or HDPE.
- containers made of materials containing relatively high content of LDPE is more readily squeezable than container made of materials containing relatively low content of LDPE.
- the container can be bottle, a vial, or syringe.
- the container is preferably a "small volume" bottle.
- the term "small volume” bottle shall mean a bottle of a size sufficient to hold a quantity of liquid medicine sufficient for 1-3 topical doses per day over 1-2 months, generally about 20 mL or less.
- small volume containers include 5 mL-, 10 mL- and 15 mL- sized bottles adapted for topically administering eye drops.
- Small volume bottles made from LDPE are easier to squeeze than larger bottles, and oval bottles are easier to squeeze than round bottles.
- the liquid preparations adapted for topical ophthalmic administration are preferably packaged in oval, LDPE bottles.
- the container suitable for the invention has a fluorinated barrier layer on a surface of the body wall.
- the fluorinated barrier layer can be on the inside surface, outside surface, or both inside and outside surfaces of the container body wall. It is preferred that the container has a fluorinated barrier layer on the inside surface of the container body wall, which is the surface that is in contact with the medicinal preparation.
- the fluorinated barrier layer can cover an entire surface of the container body wall, or it can cover only a portion or portions of a surface of the body wall. It is preferred that the fluorinated barrier layer covers an entire surface of the container body wall, and it is particularly preferred that fluorinated barrier layer covers the entire inside surface of the container body wall. Generally, the fluorinated barrier layer should display no discontinuities to provide the best barrier. Minor gaps might not prove intolerable, depending upon the conditions and levels of desired barrier property.
- the fluorinated barrier layer on the container body wall can be of any thickness.
- the barrier property of the fluorinated barrier layer increases as the thickness of fluorinated barrier layer increases.
- the thickness of the fluorinated barrier layer can be varied over a wide range.
- the barrier layer can be as thin as a monomolecular layer of fluorination on a surface of the container wall.
- the thickness of the fluorinated barrier layer generally lies in the range of from about 0.1 mm to 0.5 mm, typically about 0.2 mm.
- the fluorinated barrier layer does not necessarily involve the formation of a separate identifiable layer of the barrier compound. Rather, the requisite barrier layer of fluorinated polyolefin proceeds through the formation of a continuous film of the fluorinated polyolefin.
- the fluorinated barrier layer on a surface of a container suitable for the present invention can be prepared using various methods known in the art, one of such method being fluorination process. Fluorination of polyethylene and other polymeric materials in the production of containers is well known; see for example, U.S. Pat. Nos. 4,142,032, 4,404,256; 4,264,750; 4,593,050, 4,701 ,290, 4,830,810; 4,617,077; 4,869,859, 5,073,231, 5,691,016.
- Post-Mold fluorination process manufactured containers are loaded into tightly sealed treatment chambers or reactors where air is pumped out and fluorine is introduced and allowed to react with the containers being treated. The reaction takes place under controlled conditions and allows a range of reproducible fluorination levels to be readily achieved. Containers of different styles and sizes can be mixed in a given load, as can containers of different colors.
- the Post-Mold fluorination process treats both the inside and the outside surfaces of containers which yields a double layer of protection and potential for greater barrier than the In-Line process can produce. Post-mold fluorination is the preferred process. In certain instances it may be required to subject containers to two or more fluorination cycles to get adequate barrier properties.
- Polyethylene containers of various sizes suitable for fluorination are commercially available. Examples of such a plastic containers include small spray- pump type bottles and LDPE dropper bottles of various sizes, such 5 mL, 7.5 mL, 10 mL, or 30 m, marketed by Prime Packaging.
- Polypropylene bottles were obtained from Owens-Brockway, Illinois (capacity 5 ml). Some of the bottles were sent to a company called Fluoro-Seal (Columbus, Ohio) where they were treated for fluorine-coating under a proprietary method. After the bottles were 'fluorosealed' (done at 'level 5') they were washed in dilute soap solution rinsed several times in de-ionized water and dried before use. The bottles were then filled with 3 ml of a chlorobutanol and paraben test solution (Table 4). Control samples of untreated polypropylene bottles filled with the same solution were also prepared. All samples were prepared in duplicate and put up on accelerated stability at 56°C.
- PP means polypropylene (untreated) .
- PP-FL or PP-FL5 means fluorinated polypropylene at service provider's specified level of '5'.
- LDPE low density polyethylene (untreated).
- LDPE-FL5 means low density polyethylene fluorinated at service provider's specified level of '5'. Duplicate samples were measured. The results are presented in Table 4, below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Packages (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03791689A EP1542628A1 (en) | 2002-08-29 | 2003-08-28 | Medicinal product packaging |
CA002496796A CA2496796A1 (en) | 2002-08-29 | 2003-08-28 | Medicinal product packaging |
AU2003263897A AU2003263897A1 (en) | 2002-08-29 | 2003-08-28 | Medicinal product packaging |
BR0313753-8A BR0313753A (en) | 2002-08-29 | 2003-08-28 | Medicinal product packaging |
MXPA05002363A MXPA05002363A (en) | 2002-08-29 | 2003-08-28 | Medicinal product packaging. |
JP2004532908A JP2005537094A (en) | 2002-08-29 | 2003-08-28 | Enclosed pharmaceutical products |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40684802P | 2002-08-29 | 2002-08-29 | |
US60/406,848 | 2002-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004019837A1 true WO2004019837A1 (en) | 2004-03-11 |
Family
ID=31978368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/025841 WO2004019837A1 (en) | 2002-08-29 | 2003-08-28 | Medicinal product packaging |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040079671A1 (en) |
EP (1) | EP1542628A1 (en) |
JP (1) | JP2005537094A (en) |
AU (1) | AU2003263897A1 (en) |
BR (1) | BR0313753A (en) |
CA (1) | CA2496796A1 (en) |
MX (1) | MXPA05002363A (en) |
WO (1) | WO2004019837A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052037A2 (en) * | 2006-10-24 | 2008-05-02 | Alcon Research, Ltd. | Packaging materials for formulations containing 2-pyrrolidone derivatives |
WO2010100656A2 (en) * | 2009-02-20 | 2010-09-10 | Micro Labs Limited | Storage stable prostaglandin product |
DE102009058462A1 (en) * | 2009-12-16 | 2011-06-22 | Bayer MaterialScience AG, 51373 | Producing polycarbonate injection molded body comprises introducing injection molded bodies containing polycarbonate in reactor, inerting atmosphere of reactor, introducing fluorine-inert gas mixture and evacuating and flushing the reactor |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050267423A1 (en) * | 2004-05-27 | 2005-12-01 | Russ Johnson | Ophthalmic surgery preparation system and method |
US9241918B2 (en) * | 2005-03-16 | 2016-01-26 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
FR2911329B1 (en) * | 2007-01-12 | 2009-04-17 | Rexam Pharma Soc Par Actions S | PACKAGING AND DISPENSING ASSEMBLY OF A MEDICAL LIQUID |
JP2008189632A (en) * | 2007-02-08 | 2008-08-21 | Teika Seiyaku Kk | Ophthalmic preparation |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4693396A (en) * | 1984-12-28 | 1987-09-15 | Colgate-Palmolive Company | Laminate substrate and article therefrom incorporating fluorinated polyethylene |
EP0283151A2 (en) * | 1987-02-27 | 1988-09-21 | Allergan, Inc | Prostaglandins useful for lowering intraocular pressure |
US5691016A (en) * | 1993-07-13 | 1997-11-25 | Air Products And Chemicals, Inc. | Permeation resistant containers |
US6235781B1 (en) * | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4142032A (en) * | 1977-12-29 | 1979-02-27 | Union Carbide Corporation | Process for improving barrier properties of polymers |
US4264750A (en) * | 1979-08-01 | 1981-04-28 | Massachusetts Institute Of Technology | Process for fluorinating polymers |
US4404256A (en) * | 1980-03-26 | 1983-09-13 | Massachusetts Institute Of Technology | Surface fluorinated polymers |
US4593050A (en) * | 1983-07-25 | 1986-06-03 | Massachusetts Institute Of Technology | Ultraviolet light assisted fluorination of polymer surfaces |
DE3435592A1 (en) * | 1984-09-28 | 1986-04-03 | Kautex Werke Reinold Hagen AG, 5300 Bonn | METHOD FOR PRODUCING HOLLOW BODIES FROM THERMOPLASTIC PLASTIC |
DE3511743A1 (en) * | 1985-03-30 | 1986-10-09 | Messer Griesheim Gmbh, 6000 Frankfurt | METHOD FOR PRODUCING FLUORINATED SURFACES OF POLYMERS |
DE3523137C1 (en) * | 1985-06-28 | 1986-04-30 | Audi AG, 8070 Ingolstadt | Process for inflating and fluorinating a plastic tank |
DE3640975C2 (en) * | 1986-12-01 | 1994-08-11 | Messer Griesheim Gmbh | Process for the production of fluorinated surfaces of high density polyethylene (HDPE) |
DE3739994A1 (en) * | 1987-11-25 | 1989-06-08 | Linde Ag | METHOD FOR FLUORINATING PLASTIC OBJECTS |
US4880675A (en) * | 1988-04-25 | 1989-11-14 | Air Products And Chemicals, Inc. | Hot-fillable plastic containers |
DE3840269A1 (en) * | 1988-11-30 | 1990-05-31 | Messer Griesheim Gmbh | METHOD FOR PRODUCING SMOOTH SURFACES ON OBJECTS FROM POLYMERS OF ETHYLENE, PROPYLENE, BUTADIENE AND POLYSTYRENE |
US5292754A (en) * | 1990-03-08 | 1994-03-08 | Shionogi & Co., Ltd. | Treatment for hypertension or glaucoma in eyes |
US5693283A (en) * | 1994-08-02 | 1997-12-02 | Continental Plastic Containers, Inc. | Container with recycled plastic |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US5609273A (en) * | 1995-03-03 | 1997-03-11 | Allergan, Inc. | Barrier packaging and materials therefor |
WO2002022106A2 (en) * | 2000-09-14 | 2002-03-21 | Novartis Ag | Stable ophthalmic preparation |
US6830149B2 (en) * | 2002-03-08 | 2004-12-14 | Musculoskeletal Transplant Foundation | Package with insert for holding allograft implant to preclude lipid transfer |
-
2003
- 2003-08-27 US US10/649,300 patent/US20040079671A1/en not_active Abandoned
- 2003-08-28 BR BR0313753-8A patent/BR0313753A/en not_active IP Right Cessation
- 2003-08-28 JP JP2004532908A patent/JP2005537094A/en active Pending
- 2003-08-28 AU AU2003263897A patent/AU2003263897A1/en not_active Abandoned
- 2003-08-28 MX MXPA05002363A patent/MXPA05002363A/en unknown
- 2003-08-28 WO PCT/US2003/025841 patent/WO2004019837A1/en not_active Application Discontinuation
- 2003-08-28 EP EP03791689A patent/EP1542628A1/en not_active Withdrawn
- 2003-08-28 CA CA002496796A patent/CA2496796A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4693396A (en) * | 1984-12-28 | 1987-09-15 | Colgate-Palmolive Company | Laminate substrate and article therefrom incorporating fluorinated polyethylene |
EP0283151A2 (en) * | 1987-02-27 | 1988-09-21 | Allergan, Inc | Prostaglandins useful for lowering intraocular pressure |
US5691016A (en) * | 1993-07-13 | 1997-11-25 | Air Products And Chemicals, Inc. | Permeation resistant containers |
US6235781B1 (en) * | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052037A2 (en) * | 2006-10-24 | 2008-05-02 | Alcon Research, Ltd. | Packaging materials for formulations containing 2-pyrrolidone derivatives |
WO2008052037A3 (en) * | 2006-10-24 | 2008-10-23 | Alcon Res Ltd | Packaging materials for formulations containing 2-pyrrolidone derivatives |
WO2010100656A2 (en) * | 2009-02-20 | 2010-09-10 | Micro Labs Limited | Storage stable prostaglandin product |
WO2010100656A3 (en) * | 2009-02-20 | 2010-12-16 | Micro Labs Limited | Storage stable prostaglandin product |
DE102009058462A1 (en) * | 2009-12-16 | 2011-06-22 | Bayer MaterialScience AG, 51373 | Producing polycarbonate injection molded body comprises introducing injection molded bodies containing polycarbonate in reactor, inerting atmosphere of reactor, introducing fluorine-inert gas mixture and evacuating and flushing the reactor |
Also Published As
Publication number | Publication date |
---|---|
US20040079671A1 (en) | 2004-04-29 |
EP1542628A1 (en) | 2005-06-22 |
JP2005537094A (en) | 2005-12-08 |
MXPA05002363A (en) | 2005-05-23 |
AU2003263897A1 (en) | 2004-03-19 |
CA2496796A1 (en) | 2004-03-11 |
BR0313753A (en) | 2005-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7265584B2 (en) | Methods and compositions for treating ocular hypertension and glaucoma | |
AU743607B2 (en) | Prostaglandin product | |
US6235781B1 (en) | Prostaglandin product | |
RU2482851C2 (en) | Storage of stable preparation of prostaglandin | |
US9539262B2 (en) | Ophthalmic composition comprising a prostaglandin | |
WO2004019837A1 (en) | Medicinal product packaging | |
US20050049311A1 (en) | Medicinal products comprising prostaglandin compositions and methods of packaging such compositions | |
US20050048122A1 (en) | Method for stabalizing timolol concentration | |
JP2022130153A (en) | Pharmaceutical preparation | |
JPH07196514A (en) | Preparation for treating psoriasis of improved stability | |
MXPA00002550A (en) | Prostaglandin product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2496796 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/002363 Country of ref document: MX Ref document number: 2004532908 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003791689 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003791689 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003791689 Country of ref document: EP |